https://orcid.org/0000-0001-8539-0148
TO THE EDITOR:
Women with a germline mutation in the BRCA1 or BRCA2 genes have high cumulative risks of developing breast cancer before the age of 80 years (ie, ∼72% and 69%, respectively).1 To reduce risk, an increasing proportion of BRCA1/2 mutation carriers opt for preventive mastectomy and reconstruction with breast implants. However, breast implants are associated with a strongly increased relative risk (odds ratio = 400) of anaplastic large-cell lymphoma (BIA-ALCL), with a low absolute risk of 1/7000 at age 75 years.2-4 Host susceptibility factors for BIA-ALCL are largely unknown. As we observed several women with BRCA1/2 mutations, implants and BIA-ALCL, we examined whether BRCA1/2 mutation carriership increases the risk of BIA-ALCL in women with implants.
In December 2018, we identified 49 confirmed cases of BIA-ALCL (median age, 55 years; range, 29-75) via the Dutch nationwide Pathology Database;...
REFERENCES
REFERENCES
1.
Kuchenbaecker
KB
, Hopper
JL
, Barnes
DR
, et al; BRCA1 and BRCA2 Cohort Consortium
. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
. JAMA
. 2017
;317
(23
):2402
-2416
.2.
de Boer
M
, van Leeuwen
FE
, Hauptmann
M
, et al. Breast implants and the risk of anaplastic large cell lymphoma in the breast
. JAMA Oncol
. 2018
;4
(3
):335
-341
.3.
de Jong
D
, Vasmel
WL
, de Boer
JP
, et al. Anaplastic large-cell lymphoma in women with breast implants
. JAMA
. 2008
;300
(17
):2030
-2035
.4.
Miranda
RN
, Aladily
TN
, Prince
HM
, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients
. J Clin Oncol
. 2014
;32
(2
):114
-120
.5.
van den Broek
AJ
. The Impact of BRCA1 and BRCA2 Germline Mutations on Breast Cancer in Young Women [dissertation]. Amsterdam, The Netherlands: Dutch Cancer Institute and Vrije Universiteit, 2017
.6.
Manickam
K
, Buchanan
AH
, Schwartz
MLB
, et al. Exome sequencing-based screening for BRCA1/2 expected pathogenic variants among adult biobank participants
. JAMA Netw Open
. 2018
;1
(5
):e182140
.7.
Landrum
MJ
, Lee
JM
, Benson
M
, et al. ClinVar: public archive of interpretations of clinically relevant variants
. Nucleic Acids Res
. 2016
;44
(D1
):D862
-D868
.8.
Anglian Breast Cancer Study Group
. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases
. Br J Cancer
. 2000
;83
(10
):1301
-1308
.9.
Yang
Y
, Muzny
DM
, Reid
JG
, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders
. N Engl J Med
. 2013
;369
(16
):1502
-1511
.10.
Maxwell
KN
, Domchek
SM
, Nathanson
KL
, Robson
ME
. Population frequency of germline BRCA1/2 mutations
. J Clin Oncol
. 2016
;34
(34
):4183
-4185
.11.
Heemskerk-Gerritsen
BAM
, Hooning
MJ
. Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues-author’s reply
. Breast Cancer Res Treat
. 2020
;179
(1
):253
-254
.12.
Cordeiro
PG
, Ghione
P
, Ni
A
. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants
. J Plast Reconstr Aesthet Surg
. 2020
;73
(5
):841
-846
.13.
Ghione
P
, Cordeiro
PG
, Ni A, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed after receiving textured breast implants [abstract]
. J Clin Oncol.
2019
;37
(suppl 15)
:1565
.14.
van den Broek
AJ
, Schmidt
MK
, van ’t Veer
LJ
, et al. Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients
. Ann Surg
. 2019
;270
(2
):364
-372
.15.
Wevers
MR
, Schmidt
MK
, Engelhardt
EG
, et al. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study
. Fam Cancer
. 2015
;14
(3
):355
-363
.16.
Loch-Wilkinson
A
, Beath
KJ
, Knight
RJW
, et al. Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand: high-surface-area textured implants are associated with increased risk
. Plast Reconstr Surg
. 2017
;140
(4
):645
-654
.17.
Loch-Wilkinson
A
, Beath
KJ
, Magnusson
MR
, et al. Breast implant-associated anaplastic large cell lymphoma in Australia: a longitudinal study of implant and other related risk factors
. Aesthet Surg J
. 2019
;sjz333
.18.
Magnusson
M
, Beath
K
, Cooter
R
, et al. The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants
. Plast Reconstr Surg
. 2019
;143
(5
):1285
-1292
.19.
Doren
EL
, Miranda
RN
, Selber
JCUS
, et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma
. Plast Reconstr Surg
. 2017
;139
(5
):1042
-1050
.© 2020 by The American Society of Hematology
2020
You do not currently have access to this content.
